Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 105 | 116 | +11 |
| Shares | 29.8M | 32.2M | +2.39M (+8.0%) |
| Value | $529.4M | $652.0M | +$122.5M (+23.1%) |
New holders (28)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (17)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 754,042 | $13.4M |
| Soleus Capital Management, L.P. | 250,000 | $4.44M |
| Renaissance Technologies LLC | 106,900 | $1.90M |
| UBS Oconnor LLC | 55,262 | $982.0K |
| Tudor Investment Corp Et Al | 50,000 | $888.5K |
| CIBC World Markets Corp | 50,000 | $888.5K |
| Ghisallo Capital Management LLC | 50,000 | $888.5K |
| Endurant Capital Management LP | 47,649 | $846.7K |
| Occudo Quantitative Strategies LP | 43,707 | $776.7K |
| Channing Capital Management, LLC | 21,223 | $377.1K |
| Squarepoint Ops LLC | 19,344 | $343.7K |
| HSBC Holdings PLC | 12,903 | $217.2K |
| Verition Fund Management LLC | 10,600 | $188.4K |
| Raymond James & Associates | 10,111 | $179.7K |
| Quadrant Capital Group LLC | 130 | $2.31K |
| Parallel Advisors, LLC | 43 | $764 |
| Tucker Asset Management LLC | 4 | $71 |